Assyro AI

FDA Orange Book · active-ingredient family

Leniolisib phosphate

Leniolisib phosphate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:JOENJA · NDA 217759

1

Brand (NDA)

0

Generics (ANDA)

1

Listed patents

2

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
JOENJARLDPHARMINGNDA 217759Mar 24, 2023

Marketing exclusivity (2)

  • NCENew chemical entity exclusivity (5 years)

    Mar 24, 2028

    in 1 yr 9 mo

  • ODE-430Orphan-drug exclusivity (7 years)

    Mar 24, 2030

    in 3 yr 10 mo

Listed patents (1)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8653092Feb 19, 2032in 5 yr 9 mo
SubstanceProduct

Leniolisib phosphate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.